Thrombocytopenia in Chronic Liver Disease; New Developments

Michael Naafs, A. B.

Department of Medicine, Naafs International Health Consultancy, Netherlands

Dr. Michael Naafs, A. B., Department of Medicine, Naafs International Health Consultancy, Netherlands.

Keywords: Thrombocytopenia; Chronic Liver Disease; Pathophysiology

Abstract

In this mini-review pathophysiology of thrombocytopenia in chronic liver disease (CLD) are discussed with a special emphasises on novel drug therapeutics. Two, recently approved thrombopoietin (TPO) mimetics, lusutrombopag and avatrombopag, provide clinicians a safe and effective alternative to platelet transfusions in CLD patients with thrombocytopenia who are scheduled for an elective invasive procedure. Both TPO mimetics reduced the need for platelet transfusions significantly.

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).